firc institute of molecular oncology

Tom Gonda


School of Pharmacy, University of Queensland, Brisbane Australia

Following his PhD in Adelaide, Prof. Gonda carried out postdoctoral research at UCSF with Nobel Laureate Prof. J. Michael Bishop. This position started his ongoing interest in haematology and the MYB oncogene. Prof. Gonda returned to Australia in 1982 to the Ludwig Institute, Melbourne, where he expanded his research to include retroviral vectors and cytokines.

Prof. Gonda continued these themes upon returning to Adelaide in 1990 at the Hanson Institute. From 2001-3 he gained biotechnology industry experience as Chief Scientist of Bionomics Ltd. He then returned to academia at the University of Queensland, first at the Diamantina Institute and now the School of Pharmacy. Prof. Gonda's research focuses on the role and therapeutic targeting of MYB in leukaemia and breast cancer. He has also been heavily involved in cancer gene discovery projects utilising functional genomics, genetic screens and genomic sequencing.

Prof. Gonda has contributed to the organisation of several scientific conferences including "New Directions in Leukaemia Research", which he co-founded. He has published in Nature, Cell, PNAS, EMBO J, Blood, Leukemia and Nature Reviews Cancer, and has obtained funding from major national and international agencies.


Gonda's article

June 2013

The role of MYBBP1A in early embryonic development

Commentary on Francesco Blasi's paper published on PloS one.